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B. anthracis is the causative agent of anthrax. Pathogenesis is primarily mediated through the exotoxins lethal factor and
edema factor, which bind protective antigen (PA) to gain entry into the host cell. The current anthrax vaccine (AVA, Biothrax
TM)
consists of aluminum-adsorbed cell-free filtrates of unencapsulated B. anthracis, wherein PA is thought to be the principle
target of neutralization. In this study, we evaluated the efficacy of the natural adjuvant, C3d, versus alum in eliciting an anti-PA
humoral response and found that C3d conjugation to PA and emulsion in incomplete Freund’s adjuvant (IFA) imparted
superior protection from anthrax challenge relative to PA in IFA or PA adsorbed to alum. Relative to alum-PA, immunization of
mice with C3d-PA/IFA augmented both the onset and sustained production of PA-specific antibodies, including neutralizing
antibodies to the receptor-binding portion (domain 4) of PA. C3d-PA/IFA was efficacious when administered either i.p. or s.c.,
and in adolescent mice lacking a fully mature B cell compartment. Induction of PA-specific antibodies by C3d-PA/IFA correlated
with increased efficiency of germinal center formation and plasma cell generation. Importantly, C3d-PA immunization
effectively protected mice from intranasal challenge with B. anthracis spores, and was approximately 10-fold more effective
than alum-PA immunization or PA/IFA based on dose challenge. These data suggest that incorporation of C3d as an adjuvant
may overcome shortcomings of the currently licensed aluminum-based vaccine, and may confer protection in the early days
following acute anthrax exposure.
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INTRODUCTION
Anthrax, an acute infectious disease caused by the spore-forming
bacteria B. anthracis, has come to recent prominence as an agent of
bioterrorism. Acute exposure to anthrax can be treated effectively
with antibiotics, passive antibody transfer and newly developed
biological or chemical inhibitors of anthrax toxin. However,
protection from future exposure or germination of residual spores
can only be attained by vaccination and the elicitation of a strong
humoral response. The currently licensed anthrax vaccine
(Biothrax
TM) is a cell-free filtrate derived from an avirulent
unencapsulated strain of B. anthracis and adsorbed to an aluminum
hydroxide salt (alum). While limited case studies indicate that
Biothrax
TM is protective, concerns remain regarding efficacy and
safety [1]. Approximately 30% of patients who are vaccinated with
Biothrax
TM suffer from mild skin irritation and cutaneous-
anthrax-like symptoms, which are thought to be due to toxins
present in the filtrate [2,3,4]. The vaccination regimen requires six
injections over the course of 18 months and frequent boosters to
achieve and maintain full effectiveness [4,5]. Therefore, there is an
acknowledged need for an improved vaccine that exhibits prompt
and sustained effectiveness and is free of reactogenic properties
[6]. Specifically, next generation anthrax vaccines aim to: 1)
induce rapid neutralizing antibody titers, 2) maintain high titers of
neutralizing antibody, 3) induce robust memory responses, and 4)
be free of reactogenic properties that may cause illness or
discomfort. In addition, vaccines for use in the general public
need to impart protection in infants and the elderly.
The major virulence factors of B. anthracis provide the most
promising targets for vaccine development and are encoded by 2
plasmids, pXO1 and pXO2. Plasmid pXO1 encodes the toxin
components lethal factor (LF), edema factor (EF) and protective
antigen (PA), which work collaboratively to promote anthrax
toxicity [7,8,9]. Plasmid pXO2 encodes the capsule carbohydrate
poly-c-D-glutamic acid that prevents phagocytosis, but is not
toxigenic. Toxin pathogenesis is initiated by PA binding to TEM8
or CMG2 on the macrophage cell surface to allow heptameriza-
tion of PA and subsequent association with LF or EF [7,10]. The
PA heptamer and a single LF/EF molecule form a large complex
which induces receptor-mediated internalization into endocytic
vesicles that mature into acidic lysosomes. Low pH within the
vesicle changes the conformation of PA to create a pore that allows
exit of LF or EF into the cytoplasm before degradation can occur
[8]. Edema toxin (EdTx), the combination of PA and EF,
primarily affects neutrophil function by disregulating water
homeostasis leading to edema [8]. Lethal toxin (LeTx), the
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members leading to apoptosis of the infected cell [8]. In mouse,
macrophage sensitivity to LeTx-induced apoptosis does not always
correlate with strain susceptibility to anthrax infection, indicating
that additional understanding of the pathophysiology is needed.
Protective antigen is so named for its ability to elicit a protective
immune response to anthrax infection, consistent with evidence
that protection provided by Biothrax
TM vaccination is attributed
to PA-specific antibodies [1,4]. Protective antigen has no intrinsic
enzymatic activity or pathogenic function, but is essential for the
cellular entry of LF and EF. Disruption of domain 4 (amino acids
587–735) of PA completely abrogates binding to cell surface
receptors and consequently negates toxin pathogenicity [11,12].
With the intent of curtailing side effects of Biothrax
TM and
eliciting a more robust PA-specific IgG response, one promising
new approach for an improved vaccine is to utililize recombinant
PA (rPA) instead of cell-free filtrates [1].
The only approved adjuvants in the U.S. contain aluminum
hydroxide or phosphate salts (alum) and therefore much of the
work in testing new anthrax vaccine targets have used alum
[13,14,15]. Correspondingly, relatively little attention has been
paid to the development of alternative adjuvants to augment
antigen-specific B cell responses. In seminal work, Dempsey et al
reported the use of C3d, a breakdown product of complement
serum protein C3, as a natural molecular adjuvant that
significantly augmented antigen-specific antibody titers [16]. C3d
has since been used in mice for a variety of vaccine applications
including HIV, measles, S. pneumoniae and influenza
[17,18,19,20,21,22]. C3d function is primarily mediated through
its binding to complement receptors CD21/CD35 expressed on
both B cells and follicular dendritic cells (FDCs). Though the
mechanism of C3d function has not been fully elucidated, work
from our group and others suggests that binding of complement
receptors leads to retention of antigen on the FDC or B cell surface
and prolongs signaling by the B cell receptor complex, leading to
augmented B cell activation [23,24,25,26,27,28,29].
In this study, we evaluated the use of C3d as an adjuvant for PA.
We demonstrate that conjugation of PA to trimeric C3d (C3d3)i n
the presence of IFA induces a more robust and protective IgG
response to intact PA or domain 4 as compared to PA in IFA or
PA adsorbed to alum (PA-Alum). The response elicited by C3d
conjugation occurs more rapidly and is at least as durable as PA-
alum after a single immunization. Furthermore, C3d3-PA is
effective when administered by various routes of immunization
and is functional in adolescent mice. Lastly, we find that increased
efficacy of C3d3-PA/IFA may derive in part from its ability to
augment the germinal center (GC) response and enhance B cell
differentiation into plasma cells and memory B cells.
MATERIALS AND METHODS
Mice
6–8 week old A/J, C3H/HeJ and BALB/c mice were purchased
from Jackson laboratories (Bar Harbor, ME). All animals were
maintained in a pathogen-free environment and handled in
accordance with the guidelines set forth by NIH and animal
subjects programs at the Burnham Institute for Medical Research
or UCSD.
Purification of C3d3-bio and conjugation to PA
Cloning of murine C3d and expression of the biotinylated form
(C3d3-bio) was described previously [29]. Briefly, pXA3-C3d3-bio
was transformed into BL21A1 cells and cultures grown in Luria
broth (supplemented with 50 mg/mL carbenicillin and 0.1%
glucose) to an OD of 0.4–0.6 at 30uC. C3d3-bio expression was
induced by the addition of arabinose (0.1%) and IPTG (0.5 mM).
Overexpressed protein was purified using Ni-NTA beads (Qiagen,
Valencia, CA), dialyzed against PBS, concentrated (Amicon ultra;
Millipore, Billerica, MA) and treated for endotoxin removal
(EndoClean
TM; BioVintage, San Diego, CA). Protective antigen
(BEI Resources, NIAID, Bethesda, MD) was in vitro biotinylated
(EZ link Sulfo-NHS-biotin; Pierce, Rockford, IL), subjected to
endotoxin removal and conjugated with C3d3-bio at a molar ratio
of 1:2.5 using an avidin bridge (Sigma, St. Louis, MO; hen egg
avidin expressed in plant and admixed with an equimolar amount
of PA).
Expression of PA and domain 4
DNA segments encoding full length PA (for coating of ELISA
plates) or domain 4 (amino acids 587–735) were cloned into
pET15b and expressed in BL21 DE3 cells. Cells were grown to an
OD of ,0.5 at 37uC and the culture induced with 0.2 mM IPTG
for 4 hrs after shifting and equilibrating the culture for 15 min at
30uC. Overexpressed proteins were affinity purified using Ni-NTA
agarose beads (Qiagen) binding the C-terminal His tag in both
proteins.
Immunizations
Mice received PA-Av, PA-Av-C3d [both emulsified 1:1 in IFA
(Sigma)] or PA-Av adsorbed to alum [ratio of 1:1], (Imject; Pierce).
Injection volume was 200 ml when injected i.p., 100 ml when
injected subcutaneously (s.c) and 50 ml for intramuscular (i.m.)
injections. For i.m. injections, PBS was used instead of IFA. All
mice were immunized with either 10 or 20 mg of PA, as noted in
the Results. All secondary immunizations were given the re-
spective amount of PA in PBS i.p. Immunizations of adolescent
mice were performed on groups of 2–3, 21–25 day old A/J mice.
These mice received 10 mg PA and were injected i.p. The kinetics
of GC formation and accumulation of plasma cells and activated T
cells were assessed by flow cytometry on immunized groups of 3
mice each sacrificed at 0, 2, 4, 8, or 12 days post-immunization.
ELISA
Peripheral blood was isolated from mice by retro-orbital bleed
before immunization and at 7–10 day intervals after immuniza-
tion. Serum antibody titers against PA or domain 4 were detected
using 96 well plates (BD Biosciences, San Diego, CA) coated with
either 10 mg/ml PA or domain 4 and developed with alkaline
phosphatase-conjugated rat anti-mouse IgG, IgM, IgG1, IgG2a,
IgG2b or IgG3 secondary antibodies (Southern Biotechnology,
Birmingham, AL). PNPP substrate (Southern Biotechnology) was
used for colorimetric quantification at 405 nm on a microplate
reader (ELx808, Bio-Tek, Winooski, VT). For comparisons among
animals, single point dilutions were selected following the
determination of the linear range of serum antibody binding.
Flow cytometry
Single cell spleen cell suspensions were prepared and red blood
cells removed by ACK lysis. 1.5610
6 cells were analyzed per
staining reaction and analyzed using a FACSCanto (BD
Biosciences). Stains for germinal center B cells included B220-
APC-Cy7, IgD-bio, Sav-Pcp-Cy5.5, CD3-PE-Cy7, GL7-fitc, Fas-
APC, CD11b-PE (BD Pharmingen, eBiosciences, San Diego, CA).
Stains for plasma cells substituted Syn1-PE, IgD-fitc, IgM-APC,
and CD3-fitc. T cell activation stains included ICOS-PE, CD62L-
APC, CD4-APC-Cy7 and B220-APC.
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Spleens were harvested and placed in O.C.T. (Tissue-TekH,S a k u r a
Finetek, Torrance, CA) followed by snap-freezing in liquid nitrogen.
Seven mM sections were prepared and stained and stained with
combinations of B220-APC, CD4-FITC, IgM-APC, IgD-FITC,
CD35-bio, GL7-FITC (BD-pharmingen; eBioscience). Images were
acquired using a Zeiss Axiocam M1 microscope/10X objective and
Slidebook software (Intelligent Imaging Innovations, Denver, CO).
Mouse challenge with B anthracis
Spores were prepared from the Sterne strain of B. anthracis
(pXO1
+pXO2
2) as previously described [30]. Prior to infection,
the spores were heated to 65uC for 30 min to activate spores for
germination. Groups of female A/J mice were immunized i.p. as
described above and challenged 10 days later by intranasal
administration of 20 ml of the B. anthracis spore preparation
containing the indicated inoculum. Survival was monitored for
10 days after infection.
RESULTS
C3d3 conjugation to PA is superior to alum
adsorption in eliciting antibody responses to intact
PA and domain 4
To determine if C3d3 is an effective adjuvant for PA vaccination,
we compared B cell immune responses in mice from several strains
immunized with: PA-alum, PA-C3d3/IFA or PA in IFA. For
preparation of the immunogen, full length (83 kD) PA was in vitro
biotinylated and either conjugated to biotinylated-C3d3 via an
avidin (Av) bridge (PA-Av-C3d3) and emulsified in IFA, com-
plexed with Av and adsorbed to alum (PA-Av-Alum) or complexed
in the presence of Av and emulsified in IFA. Groups of A/J,
BALB/c, and C3H/HeJ mice were immunized intraperitoneally
(i.p.) with equivalent amounts (20 mg) of PA and PA-specific IgG
measured by ELISA. In all strains of mice, PA-Av-C3d3/IFA
elicited a markedly greater IgG response than PA-Av-Alum or
PA/IFA during the primary response (Figure 1A). Elevated titers
of PA-specific IgG were observed by 7 days after initial
immunization with PA-Av-C3d3/IFA - approximately 2.5- to 3-
fold enhanced over PA-Av-Alum immunization. Peak IgG titers
were observed between days 14 and 21 in PA-Av-C3d3/IFA
immunized mice. At day 42, all groups received a boost of PA in
saline. Mice receiving PA-Av-Alum showed a clear secondary
response, indicating that although alum did not provide a robust
primary IgG response, it was capable of priming a secondary
response. In contrast, secondary immunization of PA-Av-C3d3/
IFA-primed mice with soluble PA maintained the elevated specific
IgG titers observed during the primary immunization. High levels
of PA-specific titers remained in the serum of C3d-immunized
mice for over 60 days post-secondary immunization (data not
shown). Results from the immunization of C3H/HeJ mice also
demonstrated that preparation of the C3d adjuvant was free of
LPS endotoxin contamination as these mice express a nonfunc-
tional TLR4 protein [31]. Curiously, PA-Av/IFA elicited strong
IgG responses in A/J mice in both the primary and secondary
responses. However, PA/IFA alone (non biotinylated, no Av)
elicited similar IgG responses (data not shown), and BALB/c and
C3H/HeJ mice did not respond well to PA-Av/IFA. Therefore,
we conclude that A/J is a high-responder strain to PA, and that
the C3d-adjuvant effect is not due to multimerization of PA or the
use of IFA (data not shown). Most Importantly, C3d elicited
a consistent 2.5-3 fold greater primary antibody response as
compared to alum, regardless of the mouse strain used.
Antibodies specific for domain 4 of PA are capable of neutralizing
toxin by blocking binding of the toxin to host cell surface receptors
[10,32,33]. Indeed, passive protection from anthrax exposure is
conferred by injection of monoclonal antibody 14B7, which binds to
this region with high affinity [32]. We therefore tested whether
immunization with PA-Av-C3d3/IFA efficiently produced domain
4-specific antibodies (Figure 1B). In all strains of mice tested (A/J,
BALB/c, and C3H/HeJ), primary immunization with PA-Av-
C3d3/IFA elicited an approximately 3-fold enhancement in domain
4-specific IgG titers relative to PA-Av-Alum or PA-Av/IFA
(Figure 1B). Secondary immunization of A/J and C3H/HeJ mice
with soluble PA alone did not further elevate the existing high titers
of domain 4-specific antibody present in PA-Av-C3d3/IFA-immu-
nized mice. However, BALB/c mice did show a modest increase in
domain 4-specific IgG after the boost (Figure 1B).
To quantitate antigen-specific titers in PA-Av-C3d3/IFA
immunized mice, endpoint ELISAs were also performed on serum
isolated during the peak primary response (day 14) from all
immunized mice. In all strains of mice, we confirmed that PA-Av-
C3d elicits a 3-5 fold increase in PA- or domain 4-specific
antibodies as compared to PA-Av-Alum or PA/IFA (Figure 1C).
Altogether, these data indicate that C3d3/IFA is a more effective
adjuvant combination than alum in eliciting a rapid and sustained
antibody response to PA and, in particular, neutralizing antibodies
to domain-4 after a single immunization. The adjuvant effect is
chiefly attributed to C3d rather than IFA, since emulsion of PA-Av
in IFA does not elicit a significantly enhanced antibody response
relative to PA-Av in PBS (data not shown).
PA-Av-C3d3 augments production of isotype
switched antibody
To determine adjuvant-dependent differences in generating
neutralizing class-switched domain 4-specific antibodies, antigen-
specific ELISAs were performed to measure IgM and IgG titers in
A/J mice immunized with PA-Av/IFA, PA-Av-Alum or PA-Av-
C3d3/IFA (Figure 2). We observed that C3d3-conjugation
dramatically enhanced domain 4-specific IgM and all IgG
subtypes during the primary response. At day 14, PA-Av-C3d3/
IFA induced, at minimum, a 2-fold increase in serum IgM, IgG1,
IgG2a, IgG2b and IgG3 titers as compared to PA-Av-Alum or PA-
Av/IFA. However, following the boost at day 49, C3d3 adjuvant
only increased serum titers of IgM and IgG3 relative to alum
(Figure 2). A similar isotype distribution was observed for
antibodies binding intact PA (data not shown).
PA-Av-C3d is effective when administered via
intraperitoneal or subcutaneous routes
The adjuvant function of C3d is primarily mediated through its
high affinity interaction with complement receptor CR2 (CD21/
35) expressed on B cells and FDCs [34,35]. However, B cells and
FDCs are not likely to be present at sites of subcutaneous (s.c.) or
intramuscular (i.m.) delivery, which are the sites of administration
for the Biothrax
TM and rPA102 vaccines [4,36]. Therefore, we
determined how delivery of C3d3 by these routes would compare
with the potency observed after i.p. injection. Interestingly, we
found that PA-Av-C3d3/IFA produced equivalent titers of anti-PA
IgG antibodies when administered via i.p. or s.c. routes, but
showed reduced effectiveness i.m. (Figure 3A). Similar findings
were obtained for domain 4-specific IgG (Figure 3B). In
comparative analyses, anti-PA titers from mice immunized s.c.
with PA-Av-C3d3/IFA were elevated 3-fold relative to PA-Av-
Alum (Figure 3C). Intramuscular immunization with PA-Av-C3d3
or PA-Av-Alum produced similar responses (Figure 3D). These
C3d-Based Anthrax Vaccine
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1044Figure 1. Immunization with PA-Av-C3d3/IFA augments production of PA- and Domain 4-specific antibodies relative to alum. Groups of A/J (top),
BALB/c (middle), and C3H/HeJ (bottom) mice were immunized with PA-Av/IFA (#), PA-Av-Alum (%), or PA-Av-C3d3/IFA (n). (A) Serum PA- and (B)
Domain 4-specific IgG was measured by ELISA (Abs 405 nm). All mice were boosted at day 42 (q) with PA in saline. Error bars indicate SEM (n=5). (C)
Endpoint ELISAs were performed on day 14 serum samples from PA-Av/IFA, PA-Av-Alum, and PA-Av-C3d3/IFA immunized mice. Endpoint titers
shown are 2-fold above background. Error bars represent SEM (n=5, *p#0.05, ** p#0.01, *** p#0.005).
doi:10.1371/journal.pone.0001044.g001
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when administered s.c, and is comparable to alum when injected
i.m.
PA-Av-C3d elicits strong antibody responses in
adolescent mice
Another key parameter in vaccine development is safety and
efficacy in infants and children. We therefore investigated whether
C3d would be an effective adjuvant in adolescent mice, which lack
a fully mature B cell compartment. In particular, marginal zone B
cells (MZBs), which line the splenic marginal sinus and respond to
blood born antigens, are underrepresented in the young. This is an
important consideration since MZBs express high levels of CD21
and may be key mediators of C3d function [37,38]. Character-
ization of B cell compartments in 3-week old A/J mice showed an
over-abundance of immature-mature ‘‘transitional’’ B cells in the
spleen; however follicular structure and B/T segregation was
intact (data not shown). As expected, MZBs were present, but at
a lower frequency than in adult mice (data not shown). Twenty-
two day old A/J mice were immunized i.p. with equivalent
amounts of PA (10 mg) in the form of PA-Av/IFA, PA-Av-Alum,
or PA-Av-C3d3/IFA. Serum was collected every 10 days and PA-
and domain 4-specific IgG titers measured by ELISA
(Figure 4A,B). As seen in adult mice, PA-Av-C3d3/IFA elicited
greater PA- and domain 4-specific IgG than PA-Av/IFA or
PA-Av-Alum (Figure 4A,B). The kinetics of the response was
also similar to adult mice insofar as significant levels of IgG
were detected by day 10 and increased through day 20
(Figure 4A,B). Conversely, alum-immunized mice mounted
minimal PA- and domain 4-specific antibody responses. PA-Av/
IFA also induced PA-specific IgG; however minimal domain 4-
specific IgG was detected. Thus C3d3 is an effective adjuvant in
adolescent mice.
Figure 2. Immunization with PA-Av-C3d3/IFA augments production of isotype switched antibody. Domain 4-specific IgM, IgG1, IgG2a, IgG2b and
IgG3 ELISAs (Abs 405 nm) were performed from A/J mice immunized with PA-Av/IFA (#), PA-Av-Alum (%), or PA-Av-C3d3/IFA (n). All error bars
indicate SEM (n=5).
doi:10.1371/journal.pone.0001044.g002
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formation of germinal centers and plasma cell
differentiation
Germinal centers (GCs) are specialized structures within follicles
wherein B cells undergo somatic hypermutation and class switch
recombination of rearranged immunoglobulin genes to generate
high-affinity plasma cells or memory B cells [39]. To address how
C3d3 enhances the antibody response, we investigated the effect of
C3d conjugation versus alum adsorption on the formation of GCs
and plasma cells. Groups of A/J mice were immunized with PA-
Av-Alum or PA-Av-C3d3/IFA and analyzed by flow cytometry
and immunohistology at 0, 2, 4, 8 and 12 days post-immunization
to enumerate splenic GCs, plasma cells and activated T cells.
Serum was collected from all mice and PA- and domain 4-specific
IgG titers determined by ELISA (Figure 5).
Analysis of PA–Av-Alum- and PA-Av-C3d3/IFA-immunized
mice showed that immunization with C3d3 enhanced the
generation of GL7
+, Fas
+ GC B cells (Figure 5A). Peak GC B
cell production occurred on day 8 (0.16%) in PA-Av-C3d3/IFA-
immunized mice and was approximately 3-fold greater than in
PA-Av-Alum-immunized mice (0.05%) (Figure 5A). At day 12,
differentiation into GC B cells was increased in PA-Av-Alum-
immunized mice, while PA-Av-C3d3/IFA-immunized counter-
parts maintained the high percentage of GC B cells seen at day 8.
Immunofluorescent staining of spleen sections corroborated the
flow cytometric data and showed that PA-Av-C3d3/IFA immu-
nization elicited larger and more frequent GCs than PA-Av-Alum-
immunized counterparts (data not shown). Although PA-Av/IFA
immunizations were not included in this experiment, these
findings in conjunction with the PA-specific IgG responses shown
in Figure 1 support the conclusion that C3d3 conjugation hastens
the onset and promotes the maintenance of the GC reaction.
In addition to GC formation, C3d3 conjugation also promoted
plasma cell generation more efficiently than alum, as evidenced by
the increased (4-fold) generation of B220
lo, Syn1
hi B cells as soon
as 2 days post-immunization (Figure 5B). Peak plasma cell
formation in PA-Av-Alum immunized mice (5.2%) was observed
at day 4 after immunization, whereas PA-Av-C3d3/IFA induced
peak plasma cell levels at day 8 (8%) (Figure 5B). Furthermore,
a high percentage of plasma cells was maintained through day 12
in PA-Av-C3d3/IFA immunized mice. Determination of serum
PA- and domain 4-specific IgM and IgG titers corroborated the
plasma cell data as PA-Av-C3d3/IFA immunization induced a 3-
fold increase in PA-specific IgM and IgG at day 8 as compared to
alum (Figure 5D,E). Domain 4-specific IgM and IgG showed
a significant 2-fold increase at day 8 (Figure 5F,G). These data are
consistent with the magnitude and kinetics of the anti-PA/domain
4 responses shown in Figure 1.
Analysis of in vivo T cell activation in PA-Av-C3d3/IFA and PA-
Av-Alum immunized mice revealed similar percentages of
activated T cells (CD62L
lo, ICOS+) (Figure 5C), though the
subset of PA-specific T cells was not assessed. We speculate that
the augmented GC reaction and plasma cell formation is through
direct B cell activation by co-ligation of C3d3 and the BCR, as well
as CD21-facilitated uptake of antigen for presentation to T cells.
No evidence of elevated TNFa, IL1-b or IL-6 was observed in the
serum of PA-Av/IFA, PA-Av-Alum, or PA-Av-C3d3/IFA immu-
Figure 3. PA-Av-C3d3 is an effective immunogen delivered i.p., s.c or i.m. PA-Av-C3d3 was injected i.p. (n), s.c. (&), or i.m. (¤) and (A) PA- or (B)
Domain 4-specific IgG was measured by ELISA. Relative efficacy of PA-Av-C3d3 (&,¤) and PA-Av-alum (%,e) was compared following (C) s.c. or (D)
i.m. administration of immunogen (see methods). Error bars indicate SEM (*p#0.05, ** p#0.01, *** p#0.005, n=3).
doi:10.1371/journal.pone.0001044.g003
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the time points shown in Figure 5, indicating that C3d3 is not
generally pro-inflammatory (data not shown).
PA-Av-C3d3 provides enhanced protection against
aerosol anthrax spore challenge
To test the efficacy of the antibody response elicited by PA-Av-
C3d3/IFA immunization, we compared the ability of the various
immunogens to provideprotection againstintranasal Sterne strainB.
anthracis spore challenge. Groups of mice were immunized i.p. with
either Av in IFA (Av/IFA), PA-Av/IFA, PA-Av-Alum, or PA-Av-
C3d3/IFA. 10-days post immunization, mice were given approxi-
mately 5610
5 anthrax spores administered intranasally (Figure 6A).
Control mice (Av/IFA-immunized) survived for only 4-days
following anthrax challenge. Forty percent of PA-Av/IFA immu-
nized mice survived anthrax challenge, with most deaths occurring
between day 4 and 5. PA-Av-Alum immunization provided slightly
enhanced protection (60% survival) relative to the PA/IFA, with
most deaths occurring at approximately 6 days after anthrax
challenge. PA-Av-C3d3/IFA immunization was the most effective,
showing 80% survival from B. anthracis spore challenge.
Finally, we asked whether the enhanced antibody response
elicited by PA-Av-C3d3/IFA immunization (Figure 1 & 2) could
protect mice from increased spore dose. Therefore, we challenged
mice with a 10-fold increase (5610
6) in Sterne strain B. anthracis
spores (Figure 6B). We observed that mice immunized with PA-
Av-C3d3/IFA exhibited 90% survival, indicating that C3d is an
effective adjuvant against high-dose spore challenge. PA-Av-Alum
and PA-Av/IFA immunized mice showed only 40% and 30%
survival, respectively. Taken together, these data suggest that
incorporation of C3d confers increased vaccine efficacy relative to
Figure 4. C3d is a functional adjuvant in adolescent mice. 3-week old A/J mice were immunized with PA-Av/IFA (#), PA-Av-Alum (%), or PA-Av-
C3d3/IFA (n). (A) PA-specific IgG or (B) domain-4 specific IgG was measured by ELISA up to 20 days after primary immunization. Error bars indicate
average of 2 mice/group, and was repeated twice.
doi:10.1371/journal.pone.0001044.g004
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PLoS ONE | www.plosone.org 7 October 2007 | Issue 10 | e1044Figure 5. C3d conjugation augments the formation of germinal centers and plasma cells. A/J mice were analyzed at the indicated time points
post-immunization with PA-Av-Alum or PA-Av-C3d3/IFA. Flow cytometry profiles indicate (A) percent splenic germinal center B cells (CD3
2, CD11b
2,
IgD
2, B220
+, GL7
+, Fas
+) of total B cells; (B) percent plasma cells (CD11b
2, CD3
2, IgD
2, B220
lo, Syn1
hi) of IgD
2 B cells, and (C) percent activated T cells
(B220
2, CD11b
2, CD4
+, CD62L
lo, ICOS
+) of CD4
+ cells. Representative FACS plots are shown with average and standard deviation (n=3) of gated
population indicated. ELISAs were performed to measure PA-specific (D) IgM and (E) IgG and domain 4-specific IgM (F) and IgG (G) from serum of
mice immunized with PA-Av-Alum (white columns) or PA-Av-C3d3/IFA (black columns). Error bars represent SEM (n=3) (*p#0.05, **p#0.01,
***p#0.005).
doi:10.1371/journal.pone.0001044.g005
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anthrax challenge.
DISCUSSION
To avoid a calamitous outcome from B. anthracis infection, the
humoral immune system needs to respond rapidly and effectively
to limit or prevent pathogenic effects of anthrax toxins. If
administered prior to the symptomatic stage, antibiotics are
effective in stemming disease. However, since these symptoms are
nonspecific, effective prophylactic vaccines are necessary to
prevent spore germination, block vegetative replication and/or
neutralize exotoxin function. The currently licensed Biothrax
TM
vaccine consists of aluminum hydroxide-adsorbed culture super-
natant material from toxigenic unencapsulated strains of B.
anthracis. In response to the acknowledged threat of B. anthracis
spore dissemination as a biowarfare agent, usage of Biothrax
TM for
active vaccination programs and for prospective stockpiling has
accelerated. The resurgent need for an anthrax vaccine(s) has also
refocused concerns regarding the specific efficacy and nonspecific
reactogenicity associated with vaccination. In response to the
stated need to develop a well characterized and efficacious vaccine
that is also well tolerated [6], we generated and characterized
a novel subunit vaccine that employs C3d as a natural adjuvant
and PA as the target antigen for neutralizing antibodies. In
comparison to PA-Av-Alum or PA-Av/IFA, injection of PA-Av-
C3d3/IFA by various routes of administration induced a more
rapid and augmented PA-specific antibody response. Production
of effector antibodies of all IgG isotypes was sustained, and no
evidence of pro-inflammatory cytokines was observed.
Second generation anthrax vaccines currently in clinical trials
consist of PA adsorbed to aluminum hydroxide. Hence, the
adjuvant is the same as that used in Biothrax
TM, but lot variability
in PA content as well as residual toxicity are reduced. Protective
antigen is an attractive neutralization target since binding, uptake,
and cytosolic release of LeTx and EdTx are dependent upon PA.
We found that coupling of C3d to PA and emulsion in IFA elicited
a rapid PA-specific antibody response in adult and adolescent mice
that was superior to the response elicited by equivalent amounts of
PA adsorbed to alum or emulsified in IFA. All IgG isotypes were
efficiently induced by PA-Av-C3d3/IFA, indicating that sufficient
T cell help was recruited to promote class switch recombination
and continued differentiation into plasma cell effectors. Corre-
spondingly, C3d conjugation enhanced the generation of GC B
cells and the coincident generation of Syn1
+ plasma cells.
Rechallenge with PA in saline induced similar titers of PA-specific
antibody in mice receiving primary immunizations of PA-Av-
C3d3/IFA or PA-Av-Alum. These results could indicate the
equivalent generation and survival of PA-responsive B cells from
the primary response. However, we find it more likely that the
sustained levels of anti-PA titers at 6 weeks post-immunization
with PA-Av-C3d3/IFA leads to rapid binding and clearance of PA
by Fcc receptor-bearing effector cells, resulting in reduced
availability of antigen in PA-Av-C3d3/IFA–primed animals.
Unlike PA-Av-Alum or PA-Av/IFA, PA-Av-C3d3/IFA immuni-
zation was also capable of inducing rapid and sustained IgG titers
against domain 4 of PA. This is an important hallmark, as domains
2 and 4 cooperate to bind the anthrax receptor and thus are
indispensable for anthrax toxicity [10]. These findings imply that
PA-Av-C3d3/IFA should be effective against natural or engi-
neered variants of B. anthracis.
Adjuvants are necessary to augment the immune response by
promoting lymphocyte activation and preventing rapid clearance
(‘‘depot effect’’) of the immunogen. Despite the fact that aluminum
salts have been in use for decades and are the only approved
vaccine adjuvants in the U.S., little is known about how they act.
Although some proteins adsorb to aluminum hydroxide with high
efficiency, several reports have shown rapid desorption in vivo [40].
Such findings argue against a strong depot effect and suggest that
adjuvancy may be achieved by the release of concentrated antigen.
Microbial pathogens activate the innate immune system by
engaging Toll-Like Receptors (TLRs), resulting in cytokine release
and the upregulation of costimulatory molecules on antigen-
presenting cells. It has been observed that aluminum compounds
can promote the maturation or activation of myeloid antigen-
presenting cell subsets; however, since TLR signaling does not
appear to be involved it is unclear how this occurs [40,41,42,43].
By contrast TLR signaling is thought to be a major contributor to
the immunostimulatory activity of complete Freund’s adjuvant
(CFA), consisting of paraffin oil and mycobacterial components.
CFA efficiently promotes the maturation and activation of myeloid
cells and thus promoting their ability to act as antigen presenting
Figure 6. PA-Av-C3d3 provides enhanced protection against aerosol
anthrax spore challenge. A/J mice were immunized with either:
adjuvant control (*), PA-Av/IFA (#), PA-Av-Alum (%), or PA-Av-C3d3/
IFA (n). Ten days after immunization, mice were challenged with (A)
5610
5 (10–40x LD50, n=5 per group) or (B)5 610
6 (100–4006LD50,
n=10 per group) Sterne B. anthracis spores administered intranasally.
Mouse survival was monitored for 10 days post-spore challenge.
doi:10.1371/journal.pone.0001044.g006
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of the immunogen, but nonspecific immunostimulatory activity is
minimal or absent in most preparations. We chose IFA emulsion
for the work presented here, since we sought to determine the
antigen-specific adjuvant activity of C3d in the absence of other
costimuli. Since emulsion of PA-Av in IFA generally did not elicit
an antibody response that was significantly greater than that of
PA-Av alone, it is evident that the adjuvancy effect of PA-Av-
C3d3/IFA is mainly attributed to C3d rather than IFA. Nonethe-
less, parallel studies using PA-Av-C3d3 in saline would be
necessary to formally address the role of IFA in potentiating the
effect of C3d conjugation.
In contrast to aluminum hydroxide, the adjuvancy effect of C3d
is better understood [35]. Soluble proteins generally do not
activate the complement cascade, but need to be opsonized via
antibody binding or in the context of local inflammation - as may
occur with other adjuvants that activate innate immunity. C3d
facilitates antigen retention by binding to CD21/35 on FDCs,
which do not efficiently endocytose antigen and may protect
bound antigen from proteolysis, thus creating a depot effect. In
addition to focusing antigen to the B cell surface, C3d promotes B
cell activation by co-aggregating the BCR and CD21, resulting in
enhanced signaling via CD21-associated CD19. In addition, C3d
fixation facilitates the uptake and presentation of antigen to recruit
T cell help [27,29]. It is known that CD19 and CD21 are crucial
for GC formation and resultant memory B cell generation.
Therefore, in addition to promoting the recruitment of PA-specific
B cells into the primary response, C3d-conjugation promotes the
generation of high affinity antibody-secreting cells and the
maintenance of the memory B cell compartment.
Results of a phase I trial comparing Biothrax
TM and rPA/
aluminum hydroxide (rPA102) was recently reported [17]. Toxin
neutralizing assays revealed similar efficacy with either vaccine
and reduced reactogenicity with rPA102. However, PA-specific
antibody titers were significantly reduced in subjects receiving
rPA102. Extrapolating from these findings and our own studies,
we conclude that PA-C3d conjugates or fusion proteins hold great
promise as a next generation vaccine. Unlike Biothrax
TM or
rPA102, PA-Av-C3d3 appears to elicit rapid and sustained PA-
specific antibody production when administered i.p., s.c. or i.m.,
suggesting that protection against anthrax can be achieved and
maintained with a single vaccination. Altogether, our data suggests
that PA-linked-C3d would be efficacious as both a preventative
vaccine and for the rapid induction of neutralizing antibody upon
acute anthrax exposure.
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